Skip to main content

Study Finds Surge in Non‑Primary Patents Is Building Drug‑Price Barriers

Study Finds Surge in Non‑Primary Patents Is Building Drug‑Price Barriers

THE TECH CHRONICLE  ·  technology  ·  Tuesday, September 29, 2026
Study Finds Surge in Non‑Primary Patents Is Building Drug‑Price Barriers

Food and Drug Administration (FDA).

By TechPulse Blog

A study published Monday in JAMA examined the growth of patents on small‑molecule drugs approved by the U.S. Food and Drug Administration (FDA). The researchers documented a sharp rise in the number of patents per drug, driven largely by non‑primary patents that do not cover the active ingredient. Those overlapping patents form “patent thickets” that postpone generic competition and sustain high drug prices.

Key Takeaways

  • S. Sean Tu, a drug‑and‑patent law scholar at the University of Alabama, led the research.
  • The patent analysis covered FDA‑approved small‑molecule drugs from 1990 through 2019.
  • The authors argue that the rapid expansion of non‑primary patents may curb price competition, letting brand‑name firms maintain monopoly pricing.
Metric Value Why it matters
Publication venue JAMA Peer‑reviewed platform adds credibility to the findings.
Data source FDA drug‑approval records Ensures the analysis reflects officially sanctioned medicines.
Study period 1990‑2019 Captures three decades of patent‑filing behavior.

Scope and Methodology of the Research

The team, headed by S. Sean Tu, extracted every small‑molecule drug that received FDA approval between 1990 and 2019. For each product they counted all associated patents, distinguishing “primary” claims that protect the active ingredient from “non‑primary” claims covering formulation, dosing regimens, manufacturing processes, and other peripheral aspects. By aggregating these counts, the authors could trace how the patent landscape evolved over thirty years.

Why Non‑Primary Patents Are Multiplying

While primary patents protect the core chemical entity, non‑primary patents have proliferated as companies seek additional layers of protection. The study shows that the average number of patents per drug has risen sharply, with non‑primary filings accounting for the bulk of the increase. This strategy, often termed “evergreening,” extends market exclusivity without delivering new therapeutic value.

Patent Thickets and Their Effect on Generic Entry

When a single drug is encircled by dozens of overlapping patents, generic manufacturers must navigate a complex web of legal hurdles. Each non‑primary patent can trigger separate infringement lawsuits, inflating litigation costs and delaying the launch of lower‑cost alternatives. The result is a “patent thicket” that effectively blocks competition even after the primary patent expires.

Implications for Drug Pricing and Patient Costs

By sustaining monopoly pricing, these thickets keep drug prices elevated for patients and health‑care systems. The authors contend that the surge in non‑primary patents limits price competition, allowing brand‑name firms to maintain high profit margins without introducing clinically superior products. Consequently, the financial burden on patients rises, and overall health

Reporting based on: original source.

Comments

Popular posts from this blog

Tracking your plastic: Exposing recycling myths

Tracking your plastic: Exposing recycling myths Marketplace journalists go undercover overseas and pose as recycling brokers to expose the lucrative plastic recycling business. We reveal that Malaysian companies are willing to break the law to buy Canadian plastic and show how some of it is dumped and burned in illegal landfills, where the toxic fumes and run-off appear to be making people sick. Back in Canada, we buy nine tonnes of plastic and secretly track where big companies are taking it. Will it actually get recycled? »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS Connect with CBC News Online: For breaking news, video, audio and in-depth coverage: http://bit.ly/1Z0m6iX Find CBC News on Facebook: http://bit.ly/1WjG36m Follow CBC News on Twitter: http://bit.ly/1sA5P9H For breaking news on Twitter: http://bit.ly/1WjDyks Follow CBC News on Instagram: http://bit.ly/1Z0iE7O Download the CBC News app for iOS: http://apple.co/25mpsUz Download the CBC News app for ...

Red states now legalizing recreational marijuana too

Red states now legalizing recreational marijuana too The 2020 election proved how broadly accepted recreational marijuana has become throughout the US and across party lines, with measures to legalize recreational pot breezing to victories in Arizona, New Jersey, Montana and South Dakota. (Nov. 12) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/2ImtqJ5

Two virus survivors get double lung transplants

Two virus survivors get double lung transplants A young paralegal and a car mechanic received lifesaving double lung transplants at Northwestern Medicine in Chicago after COVID-19 destroyed their lungs. (July 30) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/310Ng1O